Document Detail

Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome.
MedLine Citation:
PMID:  22483544     Owner:  NLM     Status:  Publisher    
BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors are approved for use in patients with metastatic renal cell carcinoma (mRCC) and are under investigation in several other malignancies. We assessed the incidence, clinical presentation and computed tomography (CT) findings of pneumonitis associated with mTOR inhibitors in mRCC. Correlation between radiological findings of pneumonitis and clinical outcome was also determined. METHODS: We retrospectively reviewed the clinical data and serial CT scans from patients with mRCC treated with either temsirolimus or everolimus. Serial chest CT scans were reviewed in consensus, read by two independent radiologists for the presence of pneumonitis, and corresponding clinical data were reviewed for symptoms and clinical outcome. The baseline and follow up CTs were reviewed to assess outcome to therapy. RESULTS: The study population consisted of 46pts, 21 treated with temsirolimus and 25 with everolimus (M:F 2.5:1; median 63years, range 31-79years). CT evidence of pneumonitis was seen in 14/46pts (30%), at a median of 56days on mTOR inhibitor treatment (range 31-214days). Respiratory symptoms at the time of radiographically detected pneumonitis, were observed in 7pts. Stable disease (SD) by Response Evaluation Criteria in Solid Tumours (RECIST) was achieved in 12/14pts (86%) who developed radiographic pneumonitis compared to 14/32 (44%) without pneumonitis (p=0.01) The mean change of tumour long axis size for target lesions by RECIST, normalised for 30days on therapy was -2.9% in the pneumonitis group and +4.3% in the non-pneumonitis group (p=.002). CONCLUSIONS: Preliminary data suggest that pneumonitis may be a marker of stable disease by RECIST and therefore, of therapeutic benefit. Careful patient assessment should be undertaken before the drug is discontinued.
Donnette A Dabydeen; Jyothi P Jagannathan; Nikhil Ramaiya; Katherine Krajewski; Fabio A B Schutz; Daniel C Cho; Ivan Pedrosa; Toni K Choueiri
Related Documents :
1632354 - Width of the articular cartilage of the hip: quantification by using fat-suppression sp...
14531004 - Mr appearance of cartilage defects of the knee: preliminary results of a spiral ct arth...
15159194 - Phonation offset in tracheoesophageal speech.
25271204 - Value of f-wave inversion in diagnosis of carpal tunnel syndrome and it's relation with...
24133384 - Comparison between whole-body mri and fluorine-18-fluorodeoxyglucose pet or pet/ct in o...
18682674 - Review of failed ct phantom image evaluations in 2005 and 2006 by the ct accreditation ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-5
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  -     ISSN:  1879-0852     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term functional outcome following intramedullary nailing of femoral shaft fractures.
Next Document:  Grape variety related trans-resveratrol induction affects Aspergillus carbonarius growth and ochrato...